Phase 4 data
Patients remain stable after switching to Cobenfy in open label study
Adults with schizophrenia can transition from oral atypical antipsychotics to Cobenfy (xanomeline and trospium chloride) without loss of symptom control, according to new phase 4 data from Bristol Myers Squibb.
In the 8‑week, open‑label outpatient switch study, patients who cross‑titrated to Cobenfy—using either a faster 2‑week or slower 4‑week taper—remained clinically stable, with mean Positive and Negative Syndrome Scale (PANSS) scores staying below baseline throughout the study period. No new safety signals emerged, and treatment completion was high across both strategies.
The trial enrolled 105 adults with stable schizophrenia who were switched from existing oral atypical antipsychotics to Cobenfy monotherapy. Importantly, no patients discontinued Cobenfy due to lack of efficacy, supporting its use in real‑world treatment transitions.
“Clinicians have historically had limited data to help guide these decisions,” said principal investigator David Walling, PhD. “The data presented today provide much‑needed insight into what happens during a switch to Cobenfy…patients remained stable through 8 weeks of treatment regardless of a slower or faster cross‑titration.”
The findings were presented at the 2026 Congress of the Schizophrenia International Research Society.